Media.Player

Thrombus Inhibitor

技術優勢

·       Adjuvant to “Clot busting” therapeutics. ·       Method to prevent and/or treat cardiovascular/thrombotic disease. ·       Method to treat patients undergoing invasive cardiovascular procedures (e.g., angioplasty) ·       Aegyptin inhibits thrombosis in its early stages by preventing collagen interation with the three major ligands involved in thrombus/clot formation

詳細技術說明

Available for licensing is a collagen binding protein, named aegyptin, isolated from the salivary glands of the mosquito.  Aegyptin selectively inhibits collagen-platelet aggregation, but not platelet aggregation induced by other agonists.  In a collaboration between UCI and the NIH, scientists have functionally characterized aegyptin, demonstrating it blocks the interaction of collagen with its major ligands, von Willebrand factor, glycoprotein VI (GPVI), and integrin α2β1.  These three ligands are of significant importance because they play a critical role in the early stages of thrombus formation, therefore aegyptin represents a potentially highly effective therapeutic to treat patients with thrombotic disease.  Alternatively, aegypin is potentially useful in conditions where collagen plays a critical role in angiogenesis or in conditions where excessive deposition of collagen plays a pathological role (i.e., pancreatic carcinoma).

*Abstract

Exposed collagen in injured blood vessels provides a substrate for platelets to adhere and aggregate, initiating the first step in thrombosis, the formation of blood clots inside a blood vessel.  Although platelets play an essential role in vascular injury, excessive platelet aggregation may also result in thrombotic disease such as stroke and heart attack.

*IP Issue Date

Feb 26, 2012

*Principal Investigation

Name: Osvaldo Marinotti

Department:

Name: Eric Calvo

Department:

Name: Ivo Francischetti

Department:

Name: Jose M.C. Ribeiro

Department:

附加資料

Patent Number: US8383589B2
Application Number: US2010668177A
Inventor: Calvo, Eric | Marinotti, Osvaldo | Ribeiro, Jose M. C. | Francischetti, Ivo M.
Priority Date: 9 Jul 2007
Priority Number: US8383589B2
Application Date: 7 Jan 2010
Publication Date: 26 Feb 2013
IPC Current: A61K003800 | A61K003836
US Class: 5140138 | 5140135 | 5140137
Assignee Applicant: The United States of America as represented by the Secretary Department of Health and Human Servicesshington | Regents of the University of California,Oakland
Title: Aegyptin and uses thereof
Usefulness: Aegyptin and uses thereof
Summary: The Aegyptin polypeptide, nucleic acid encoding Aegyptin polypeptide, antibody capable of specifically binding to an Aegyptin protein, and composition are useful for disrupting platelet adhesion, for reducing clot formation, for preventing metastasis, for treating or inhibiting progression of a malignant tumor, and for treating a thrombogenic disease selected from coronary thrombosis, pulmonary embolism, myocardial infarction, deep vein thrombosis, cerebral thrombosis, unstable angina, disseminated intravascular coagulation (DIC), postoperative fibrinolytic shutdown, or a rapid thrombogenic action which can occur following implantation of a medical device (all claimed).
Novelty: New nucleic acid encoding Aegyptin polypeptide, useful for treating or inhibiting progression of a malignant tumor and for treating a thrombogenic disease

主要類別

診斷/治療

細分類別

癌症/腫瘤

申請號碼

8383589

其他

Publication

 

• Aegyptin, a novel mosquito salivary gland protein, specifically binds to collagen and prevents its interaction with platelet glycoprotein VI, integrin alpha2beta1, and von Willebrand factor. J Biol Chem. 2007 Sep 14;282(37):26928-38. [PMID 17650501]

Tech ID/UC Case

22973/2010-773-0

Related Cases

2010-773-0

國家/地區

美國